WADA prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Primary antioxidants scavenge free radicals formed during the initial (thermal) oxidation process (ROO•), thus preventing chain reactions that lead to polymer degradation. Examples: butylated hydroxytoluene, 2,4-dimethyl-6-tert-butylphenol, para tertiary butyl phenol, 2,6-di-tert-butylphenol, 1,3,5-Tris(4-(tert-butyl)-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione
Another champion of the approach of developing chemical analogues of known active substances was Sir David Jack at Allen and Hanbury's, later Glaxo, who pioneered the first inhaled selective beta2-adrenergic agonist for asthma, the first inhaled steroid for asthma, ranitidine as a successor to cimetidine, and supported the development of the triptans. Gertrude Elion, working mostly with a group of fewer than 50 people on purine analogues, contributed to the discovery of the first anti-viral; the first immunosuppressant (azathioprine) that allowed human organ transplantation; the first drug to induce remission of childhood leukemia; pivotal anti-cancer treatments; an anti-malarial; an anti-bacterial; and a treatment for gout. Cloning of human proteins made possible the screening of large libraries of compounds against specific targets thought to be linked to specific diseases. This approach is known as reverse pharmacology and is the most frequently used approach today. In the 2020s, qubit and quantum computing started to be used to reduce the time needed to drug discovery.
The seeds are spherical or broadly elliptical, and are up to 0.5 mm (1⁄64 in) long with a wavy networked surface. Almost every part of the plant except the seed contains nicotine, but the concentration is related to different factors such as species, type of land, culture and weather conditions. The concentration of nicotine increases with the age of the plant. Tobacco leaves contain 2-to-8% nicotine combined as malate or citrate. The distribution of the nicotine in the mature plant is widely variable: 64% of the total nicotine exists in the leaves, 18% in the stem, 13% in the root, and 5% in the flowers.
corrects this dilution effect by multiplying the fraction of the susceptible population over the total population. It corrects the effective/transmissible interaction between an infectious person and the rest of the community when many of the interaction is immune in the middle to late stages of the disease spreading. Thus, when
29 March – A light aircraft crashes near Wānaka, killing one person. 31 March: Minister for Rail Winston Peters releases details of the two new Interislander replacement ferries, which come with rail emplacements. The New Zealand Crown settles a Treaty of Waitangi claim with Ngāti Hāua following eight years of negotiations. Treaty Negotiations Minister Paul Goldsmith apologises for historical wrongs at Ngāpūwaiwaha Marae in Taumarunui.
Sources: en.wikipedia.org
=== Water filtration === Given the water adsorption properties of silica gel, it is used in domestic water filters. The surface structure of silica gel allows the adsorption of some minerals that are dissolved in the water, or "ion exchange" as it is marketed. Due to the lack of regulations for domestic water filtration products, no studies validate the manufacturer claims regarding the effectiveness of the filtration system.
==== X-ray intensifier foils ==== In the same year as the discovery of X-rays, Mihajlo Idvorski Pupin (1858-1935) invented the method of placing a sheet of paper coated with fluorescent substances on the photographic plate, drastically reducing the exposure time and thus the radiation exposure. 95% of the film was blackened by the intensifying film and only the remaining 5% was directly blackened by the X-rays. Thomas Alva Edison identified the blue-emitting calcium tungstate (CaWO4) as a suitable phosphor, which quickly became the standard for X-ray intensifying film. In the 1970s, calcium tungstate was replaced by even better and finer intensifying films with rare earth-based phosphors (terbium-activated lanthanum oxybromide, gadolinium oxysulfide). The use of intensifying films in dental film production did not become widespread because of the loss of image quality. The combination with high-sensitivity films further reduced radiation exposure.
== Early life and education == Baker grew up on a cattle ranch in Montana, US. Her interests in chemistry stemmed from a determination to understand the arsenic and cyanide pollution from gold mines that affected animals on her family's ranch and local wildlife. She obtained a bachelor of science in chemistry, with a minor in mathematics from Montana State University in 2001, where she conducted research using ion mobility spectrometry in Eric Grimsrud's laboratory. She continued with research in ion mobility spectrometry in graduate school, and received a PhD in chemistry under the direction of Michael T. Bowers from University of California, Santa Barbara in 2005.
The current reviewers identified a number of basic science research areas that could be helpful in resolving some of the controversies in the field, two of which were: 1) material science aspects of deuterated metals using modern characterization techniques, and 2) the study of particles reportedly emitted from deuterated foils using state-of-the-art apparatus and methods. The reviewers believed that this field would benefit from the peer-review processes associated with proposal submission to agencies and paper submission to archival journals. Cold fusion researchers placed a "rosier spin" on the report, noting that they were finally being treated like normal scientists, and that the report had increased interest in the field and caused "a huge upswing in interest in funding cold fusion research". However, in a 2009 BBC article on an American Chemical Society's meeting on cold fusion, particle physicist Frank Close was quoted stating that the problems that plagued the original cold fusion announcement were still happening: results from studies are still not being independently verified and inexplicable phenomena encountered are being labelled as "cold fusion" even if they are not, in order to attract the attention of journalists. In February 2012, millionaire Sidney Kimmel, convinced that cold fusion was worth investing in by a 19 April 2009 interview with physicist Robert Duncan on the US news show 60 Minutes, made a grant of $5.5 million to the University of Missouri to establish the Sidney Kimmel Institute for Nuclear Renaissance (SKINR).
At 1 atm pressure, it reaches its maximum density of 999.972 kg/m3 (62.4262 lb/cu ft) at 3.98 °C (39.16 °F). Below that temperature, but above the freezing point of 0 °C (32 °F), water expands (becoming less dense) until it reaches the freezing point, at which its density in the liquid phase is 999.8 kg/m3 (62.4155 lb/cu ft). As water cools to 3.98 °C (39.16 °F), water volume decreases. As it freezes and becomes ice, water expands by about 9%, reaching a density of 917 kg/m3 (57.25 lb/cu ft). This expansion can exert enormous pressure, bursting pipes and cracking rocks. As a solid, it displays the usual behavior of contracting and becoming more dense as it cools. These unusual thermal properties have important consequences for life on earth. In a lake or ocean, water at 4 °C (39 °F) sinks to the bottom, and ice forms on the surface, floating on the liquid water. This ice insulates the water below, preventing it from freezing solid. Without this protection, most aquatic organisms residing in lakes would perish during the winter. In addition, this anomalous behavior is an important part of the thermohaline circulation which distributes heat around the planet's oceans.
Sources: en.wikipedia.org
=== Pharmacodynamics === Alazocine shows stereoselectivity in its pharmacodynamics. The (−)-enantiomer is a non-selective and high-affinity ligand of the μ-, κ-, and δ-opioid receptors (Ki = 3.0, 4.7, and 15 nM in guinea pig brain membranes) with very low affinity for the sigma σ1 receptor (Ki = 1,800–4,657 nM in guinea pig brain membranes). It acts as a moderate-efficacy partial agonist of the κ-opioid receptor (Ki = 0.4 nM, EC50 = 24 nM, and Emax = 66% for (±)-alazocine against the mouse receptor transfected in HEK293 cells) and as an antagonist of the μ-opioid receptor (Ki = 1.15 nM for (±)-alazocine against the mouse receptor transfected in HEK293 cells). It is also an agonist of the δ-opioid receptor with far lower potency (Ki = not reported, IC50 = 184 nM, and Imax = 68% for (±)-alazocine against the mouse receptor transfected in HEK293 cells). Conversely, the (+)-stereoisomer has little affinity for the opioid receptors (Ki for 1,900 nM, 1,600 nM, and 19,000 nM for the μ-, κ-, δ-opioid receptors in guinea pig brain membranes) and instead is a selective and high-affinity agonist of the σ1 receptor (Ki = 48–66 nM in guinea pig brain membranes). However, the (+)-enantiomer also shows moderate affinity for the dizocilpine (MK-801) or phencyclidine (PCP) site of the NMDA receptor (Ki = 587 nM in rat brain membranes relative to 45 nM for the σ1 receptor) and, hence, is an uncompetitive NMDA receptor antagonist as well at higher concentrations. As such, (+)-alazocine is only modestly selective as a ligand of the σ1 receptor.
USA Defence Secretary Donald Rumsfeld told an armed services committee of the Senate on 2004-05-07 that "There are a lot more photographs and videos that exist [...] I looked at them last night and they're hard to believe [...] The pictures I've seen depict conduct, behaviour that is so brutal and so cruel and so inhumane that anyone engaged in it or involved in it would have to be brought to justice." He also said that the abused detainees may be offered compensation. In a scene described as "surreal" by AFP, it was found in mid May, 2004 that US troops were handing out cash to freed prisoners along with a note stating "You have not been mistreated.". A reporter visiting the prison Camp War Horse described the tour:
== Climate change == Climate change exacerbates threats to aquatic plants through rising temperatures, altered precipitation patterns, and increased frequency of extreme weather events. Warmer temperatures can favor invasive species that outcompete native plants. For example, studies predict that the ranges of invasive species like Egeria densa and Myriophyllum aquaticum may expand significantly by 2070 due to climate change. Additionally, earlier spring warming allows invasive species to establish before native plants, giving them a competitive advantage. Climate-induced changes also affect water levels and flow regimes, impacting aquatic plant distribution and health. Droughts can reduce water availability, while intense storms can lead to increased runoff and sedimentation, both detrimental to aquatic vegetation.
chloroplast A type of small, lens-shaped plastid organelle found in the cells of green algae and plants which contains light-sensitive photosynthetic pigments and in which the series of biochemical reactions that comprise photosynthesis takes place. Like mitochondria, chloroplasts are bound by a double membrane, contain their own internal circular DNA molecules from which they direct transcription of a unique set of genes, and replicate independently of the nuclear genome.
== Naming conventions == Amines are named in several ways. Typically, the compound is given the prefix "amino-" or the suffix "-amine". The prefix "N-" shows substitution on the nitrogen atom. An organic compound with multiple amino groups is called a diamine, triamine, tetraamine and so forth. Lower amines are named with the suffix -amine.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.